Combating Multidrug-Resistant Acinetobacter baumannii: Insights from Japan, with Global Relevance
Abstract
Yusuke Yoshino,1,2 Yoshitaka Kimura,1 Fuyu Ito2 1Department of Microbiology and Immunology, Teikyo University School of Medicine, Itabashi, Tokyo, Japan; 2Asia International Institute of Infectious Disease Control, Teikyo University, Itabashi, Tokyo, JapanCorrespondence: Yusuke Yoshino, Department of Microbiology and Immunology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi, Tokyo, 1738605, Japan, Tel +81-3-3964-1211 ext. 47261, Email [email protected]: Acinetobacter baumannii is a non-fermentative Gram-negative bacillus known for its environmental persistence, rapid acquisition of multidrug resistance (MDR), and high outbreak potential. The 2024 World Health Organization priority pathogen list places it in the highest “Critical” tier. This review summarizes definitions, resistance mechanisms, epidemiology in Japan and abroad, diagnostic approaches, infection control, and current or emerging therapies. Carbapenem resistance is largely mediated by OXA-type carbapenemases, often together with additional mechanisms. While isolates in Japan still show comparatively high susceptibility to key agents, many Asia-Pacific and Latin American settings report substantially higher resistance. Phenotypic and molecular diagnostic tools remain essential for outbreak control. Despite the availability of several established and novel agents, no universally accepted regimen exists, and combination therapy is often necessary. This observed gap in resistance…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.